MabionWAR:MAB +0.81%30 Days Payable is 66.55 as of Mar. 2026, which is 71% below its 10-year median of 230.91. GuruFocus rates WAR:MAB with a GF Score™ of 30/100 and a GF Value™ of zł2.10 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Mabion ranks worse than 70.45% on this metric.
Mabion's average Accounts Payable for the
three
months ended in Mar. 2026 was zł5.41 Mil. Mabion's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł7.42 Mil.
Hence, Mabion's Days Payable for the
three
months ended in Mar. 2026 was 66.55.
The historical rank and industry rank for Mabion's Days Payable or its related term are showing as below:
WAR:MAB'
s Days Payable Range Over the Past 10 Years
Min: 47.04 Med: 230.91 Max: 6471.77
Current: 47.04
During the past 13 years, Mabion's highest Days Payable was 6471.77. The lowest was 47.04. And the median was 230.91.
WAR:MAB's Days Payable is ranked worse than 70.45% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs WAR:MAB: 47.04
Mabion's Days Payable
increased
from Mar. 2025 (36.26) to Mar. 2026 (66.55).
It may suggest that Mabiondelayed paying its suppliers.
Mabion Days Payable Related Terms
Mabion Days Payable Historical Data
* Premium members only.
The historical data trend for Mabion's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MAB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Mabion's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabion Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabion's Days Payable distribution charts can be found below:
* The bar in red indicates where Mabion's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mabion's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabion (WAR:MAB) has a Days Payable of 66.55 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mabion and its competitors. This is 71% below median its historical median of 230.91. Over the past decade, Mabion's Days Payable has ranged from 47.04 to 6,471.77. According to the industry distribution chart, Mabion ranks #496 out of 704 companies in the Biotechnology industry, placing it in the top 70.5%.
Is Mabion's Days Payable too high?
Mabion's current Days Payable of 66.55 is 71% below median its 10-year median of 230.91. Over the past 10 years, this metric has ranged from a low of 47.04 to a high of 6,471.77. The Biotechnology industry median Days Payable is 113.56. Mabion's value of 66.55 is 41.4% below this industry median. Based on the distribution chart, Mabion ranks #496 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mabion has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabion ranks #496 out of 704 companies for Days Payable. This places Mabion in the lower half of its industry. The industry median Days Payable is 113.56. Mabion's value of 66.55 is 41.4% below this benchmark. Historically, Mabion's own Days Payable has ranged from 47.04 to 6,471.77 over the past decade. While the company's 10-year median is 230.91 vs. the industry median of 113.56, Mabion has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mabion's current Days Payable of 66.55 is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mabion and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabion's current Days Payable is 66.55, which is 71% below median its own 10-year median of 230.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.10, compared to a current price of zł7.46 — trading 255.2% above its estimated fair value. The current Days Payable is 66.55, which is 71% below median its 10-year median of 230.91 and 41.4% below the Biotechnology industry median of 113.56. Mabion's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Days Payable is 66.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabion (WAR:MAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mabion stock appears to be overvalued.
The current stock price of zł7.46 is trading 255.2% above its estimated GF Value™ of zł2.10.
GuruFocus considers Mabion to be Significantly Overvalued.
Key valuation signals for WAR:MAB:
Days Payable: 66.55 (71% below median its 10-year median of 230.91)
GF Value™: zł2.10 vs. price of zł7.46 (255.2% above fair value)
Industry Position: 41.4% below the Biotechnology median (#496 of 704)
No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
30GF Score
Get the complete analysis for WAR:MAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MAB has been successfully added to your 
